Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1582-1600

  Urva, Shweta R ^a   Yang, Victor C ^b   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Carcinoembryonic antigen (CEA); Mathematical model; PBPK; Pharmacokinetics; Physiological model; Preclinical pharmacokinetics; T84.66 anti CEA antibody; Target mediated disposition; Tumor associated antigen

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARRIER PROTEIN; MONOCLONAL ANTIBODY T84.66; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG HALF LIFE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PARAMETER; SENSITIVITY ANALYSIS; TUMOR BLOOD FLOW; TUMOR VOLUME; XENOGRAFT;

EID: 76649094549     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21918     Document Type: Article

References (53)

1. Hebbar M, Tournigand C, Lledo G, Mabro M, Andre T, Louvet C, Aparicio T, Flesch M, Varette C, de Gramont A. 2006. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). Cancer Invest 24:154-159.
2. Tsipi Ben-Kasusa BS, Selaa M, Yardenb Y. 2007. Cancer therapeutic antibodies come of age: Targeting minimal residual disease. Mol Oncol 1:42-54.
3. Morell A, Terry WD, Waldmann TA. 1970. Metabolic properties of IgG subclasses in man. J Clin Invest 49:673-680.
4. Waldmann TA, Strober W. 1969. Metabolism of immunoglobulins. Prog Allergy 13:1-110.
5. Brambell FW, Hemmings WA, Morris IG. 1964. A theoretical model of gamma-globulin catabolism. Nature 203:1352-1354.
6. Waldmann TA, Jones EA. 1972. The role of cell-surface receptors in the transport and catabolism of immunoglobulins. Ciba Found Symp 9:5-23.
7. Simister NE, Mostov KE. 1989. Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I antigen homolog. Cold Spring Harb Symp Quant Biol 54: 571-580.
8. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. 1996. Increased clearance of IgG in mice that lack beta 2-microglobulin: Possible protective role of FcRn. Immunology 89:573-578.
9. Junghans RP, Anderson CL. 1996. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93:5512-5516.
10. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. 1996. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26:690-696.
11. Tabrizi MA, Tseng CM, Roskos LK. 2006. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11:81-88.
12. Mager DE, Jusko WJ. 2001. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532.
13. Coffey GP, Fox JA, Pippig S, Palmieri S, Reitz B, Gonzales M, Bakshi A, Padilla-Eagar J, Fielder PJ. 2005. Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 33:623-629.
14. Gold P, Freedman SO. 1965. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122:467-481.
15. Hammarstrom S. 1999. The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9:67-81.
16. Prall F, Nollau P, Neumaier M, Haubeck HD, Drzeniek Z, Helmchen U, Loning T, Wagener C. 1996. CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. J Histochem Cytochem 44:35-41.
17. Metze D, Bhardwaj R, Amann U, Eades-Perner AM, Neumaier M, Wagener C, Jantscheff P, Grunert F, Luger TA. 1996. Glycoproteins of the carcinoembryonic antigen (CEA) family are expressed in sweat and sebaceous glands of human fetal and adult skin. J Invest Dermatol 106:64-69.
18. Nap M, Hammarstrom ML, Bormer O, Hammarstrom S, Wagener C, Handt S, Schreyer M, Mach JP, Buchegger F, von Kleist S, Gruner F, Sequin P, Fuks A, Holm R, Lamerz R. 1992. Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen. Cancer Res 52:2329-2339.
19. Goldenberg DM, Kim EE, DeLand FH, Bennett S, Primus FJ. 1980. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 40:2984-2992.
20. Hughes K, Pinsky CM, Petrelli NJ, Moffat FL, Patt YZ, Hammershaimb L, Goldenberg DM. 1997. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg 226:621-631.
21. Sharkey RM, Karacay H, Griffiths GL, Behr TM, Blumenthal RD, Mattes MJ, Hansen HJ, Goldenberg DM. 1997. Development of a streptavidin-anti- carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjug Chem 8:595-604.
22. Stein R, Goldenberg DM. 2004. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Therapeut 3:1559-1564.
23. Blumenthal RD, Osorio L, Hayes MK, Horak ID, Hansen HJ, Goldenberg DM. 2005. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother 54: 315-327.
24. Wagener C, Clark BR, Rickard KJ, Shively JE. 1983. Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: Determination of affinities and specificities of monoclonal antibodies by using biotin-labeled antibodies and avidin as precipitating agent in a solution phase immunoassay. J Immunol 130:2302-2307.
25. Garg A, Balthasar JP. 2007. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687-709.
26. Antohe F, Radulescu L, Gafencu A, Ghetie V, Simionescu M. 2001. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol 62:93-105.
27. McCarthy KM, Lam M, Subramanian L, Shakya R, Wu Z, Newton EE, Simister NE. 2001. Effects of mutations in potential phosphorylation sites on transcytosis of FcRn. J Cell Sci 114:1591-1598.
28. Praetor A, Ellinger I, Hunziker W. 1999. Intracellular traffic of the MHC class I-like IgG Fc receptor, FcRn, expressed in epithelialMDCKcells. J Cell Sci 112:2291-2299.
29. Rojas R, Apodaca G. 2002. Immunoglobulin transport across polarized epithelial cells. Nat Rev Mol Cell Biol 3:944-955.
30. Raghavan M, Chen MY, Gastinel LN, Bjorkman PJ. 1994. Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity 1:303-315.
31. Ward ES, Zhou J, Ghetie V, Ober RJ. 2003. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol 15:187-195.
32. Baxter LT, Zhu H, Mackensen DG, Jain RK. 1994. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54:1517-1528.
33. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. 1986. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res 46:3969-3978.
34. Flessner MF, Lofthouse J, Zakariael R. 1997. In vivo diffusion of immunoglobulin G in muscle: Effects of binding, solute exclusion, and lymphatic removal. Am J Physiol 273:H2783-H2793.
35. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. 1995. Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55:4611-4622.
36. Zhou J, Johnson JE, Ghetie V, Ober RJ, Ward ES. 2003. Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. J Mol Biol 332:901-913.
37. Hansen RJ, Balthasar JP. 2003. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 92:1206-1215.
38. Zhu H, Melder RJ, Baxter LT, Jain RK. 1996. Physiologically based kinetic model of effector cell biodistribution in mammals: Implications for adoptive immunotherapy. Cancer Res 56:3771-3781.
39. Chung JK, Jang JJ, Lee DS, Lee MC, Koh CS. 1994. Tumor concentration and distribution of carcinoembryonic antigen measured by in vitro quantitative autoradiography. J Nucl Med 35:1499-1505.
40. Shockley TR, Lin K, Nagy JA, Tompkins RG, Yarmush ML, Dvorak HF. 1992. Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. Cancer Res 52:367-376.
41. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, Weinstein JN. 1992. Micro-pharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier. Cancer Res 52:5144-5153.
42. Hansen RJ, Balthasar JP. 2002. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 88:898-899.
43. D'Argenio DZ, Schumitzky A. 1997. ADAPT II user's guide: Pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simualtion Resource.
44. Emond C, Birnbaum LS, DeVito MJ. 2006. Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD. Environ Health Perspect 114:1394-1400.
45. Jensenius JC, Williams AF. 1974. The binding of anti-immunoglobulin antibodies to rat thymocytes and thoracic duct lymphocytes. Eur J Immunol 4:91-97.
46. Friedrich SW, Lin SC, Stoll BR, Baxter LT, Munn LL, Jain RK. 2002. Antibody-directed effector cell therapy of tumors: Analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia 4:449-463.
47. Lammerts van Bueren JJ, Bleeker WK, Bogh HO, Houtkamp M, Schuurman J, van de Winkel JG, Parren PW. 2006. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: Implications for the mechanisms of action. Cancer Res 66:7630-7638.
48. Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L. 2006. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 23:95-103.
49. Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H, Graham MA, Geboes K, Rousselle SD, Wagner CL. 2005. Formation, distribution, and elimination of infliximab and antiinfliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 313:578-585.
50. Halpern SE, Hagan PL, Garver PR, Koziol JA, Chen AW, Frincke JM, Bartholomew RM, David GS, Adams TH. 1983. Stability, characterization, and kinetics of 111In-labeled monoclonal antitumor antibodies in normal animals and nude mousehuman tumor models. Cancer Res 43:5347-5355.
51. Ferl GZ, Wu AM, DiStefano JJ III. 2005. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 33:1640-1652.
52. Ferl GZ, Kenanova V, Wu AM, DiStefano JJ III. 2006. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Therapeut 5:1550-1558.
53. Dedrick RL. 1973. Animal scale-up. J Pharmacokinet Biopharm 1:435-461.